StockData
Provectus Biopharmaceuticals, Inc. logo

Provectus Biopharmaceuticals, Inc. (PVCT) stock

PVCTOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$0.05+0.00 (+0.39%)

Close on Oct 19, 2026Market cap $20.55MP/E –Yield –

Provectus Biopharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Provectus Biopharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.08M, down 53.2% year over year. For fiscal 2025 it was $1.90M, down 7.5% from the year before. Over ten years it grew -16.4% a year on average. The highest annual figure on record is $11.38M in fiscal 2015.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.90M-7.5%
FY2024Dec 31, 2024$2.05M+17.2%
FY2023Dec 31, 2023$1.75M-26.8%
FY2022Dec 31, 2022$2.39M-8.4%
FY2021Dec 31, 2021$2.61M-7.3%
FY2020Dec 31, 2020$2.81M-29.7%
FY2019Dec 31, 2019$4.00M-15.7%
FY2018Dec 31, 2018$4.75M-42.1%
FY2017Dec 31, 2017$8.20M-0.1%
FY2016Dec 31, 2016$8.21M-27.8%
FY2015Dec 31, 2015$11.38M+95.9%
FY2014Dec 31, 2014$5.81M+61.6%
FY2013Dec 31, 2013$3.60M-28.2%
FY2012Dec 31, 2012$5.01M-43.2%
FY2011Dec 31, 2011$8.81M+4.6%
FY2010Dec 31, 2010$8.42M+71.5%
FY2009Dec 31, 2009$4.91M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$131.13K-85.1%
Q1 FY2026Mar 31, 2026$333.33K-17.2%
Q4 FY2025Dec 31, 2025$268.43K-55.9%
Q3 FY2025Sep 30, 2025$345.86K-16.5%
Q2 FY2025Jun 30, 2025$880.84K+86.3%
Q1 FY2025Mar 31, 2025$402.70K-27.5%
Q4 FY2024Dec 31, 2024$608.21K+46.3%
Q3 FY2024Sep 30, 2024$413.99K+18.0%
Q2 FY2024Jun 30, 2024$472.93K+8.9%
Q1 FY2024Mar 31, 2024$555.54K+1.3%
Q4 FY2023Dec 31, 2023$415.84K+29.5%
Q3 FY2023Sep 30, 2023$350.79K-39.6%
Q2 FY2023Jun 30, 2023$434.21K-46.8%
Q1 FY2023Mar 31, 2023$548.39K-18.3%
Q4 FY2022Dec 31, 2022$321.21K-56.7%
Q3 FY2022Sep 30, 2022$580.39K-4.6%
Q2 FY2022Jun 30, 2022$816.65K+35.4%
Q1 FY2022Mar 31, 2022$671.12K+2.4%
Q4 FY2021Dec 31, 2021$741.58K+37.5%
Q3 FY2021Sep 30, 2021$608.65K-8.8%
Q2 FY2021Jun 30, 2021$602.98K-13.4%
Q1 FY2021Mar 31, 2021$655.14K-28.0%
Q4 FY2020Dec 31, 2020$539.34K-28.3%
Q3 FY2020Sep 30, 2020$667.52K-33.5%
Q2 FY2020Jun 30, 2020$696.45K-42.4%
Q1 FY2020Mar 31, 2020$909.45K-12.3%
Q4 FY2019Dec 31, 2019$751.91K-41.7%
Q3 FY2019Sep 30, 2019$1.00M+90.1%
Q2 FY2019Jun 30, 2019$1.21M+22.4%
Q1 FY2019Mar 31, 2019$1.04M-46.6%
Q4 FY2018Dec 31, 2018$1.29M-33.4%
Q3 FY2018Sep 30, 2018$528.36K-76.6%
Q2 FY2018Jun 30, 2018$987.24K-56.2%
Q1 FY2018Mar 31, 2018$1.94M+10.8%
Q4 FY2017Dec 31, 2017$1.94M+44.7%
Q3 FY2017Sep 30, 2017$2.26M-8.1%
Q2 FY2017Jun 30, 2017$2.25M–
Q1 FY2017Mar 31, 2017$1.75M–
Q4 FY2016Dec 31, 2016$1.34M–
Q3 FY2016Sep 30, 2016$2.46M–

More Provectus Biopharmaceuticals figures

See a number that looks wrong?